Table 1.
Baseline patient demographic and clinical characteristics at initiation of first TNF-α inhibitor
| Characteristic | Overall patient population (n = 141) |
|---|---|
| Age, mean (s.d.), years | 50.3 (12.1) |
| Males, n (%) | 70 (50) |
| Smokers, n (%) | |
| Current | 14 (10) |
| Former | 34 (24) |
| Never | 60 (43) |
| Unknown | 33 (23) |
| BMI, mean (s.d.), kg/m2 | 28.7 (5.4) (n=68) |
| PsA disease duration, median (IQR), years | 5.7 (2.0–11.6) (n=138) |
| Co-morbidities, n (%) | |
| Hypertension | 39 (28) |
| Obesity | 30 (21) |
| Hypercholesterolaemia | 24 (17) |
| Diabetes/high blood glucose | 17 (12) |
| Depression | 13 (9) |
| Coronary heart disease | 8 (6) |
| None | 66 (47) |
| PsA-related clinical manifestations, n (%) | |
| Psoriasis | 118 (84) |
| Peripheral arthritis | 105 (74) |
| Nail involvement | 42 (30) |
| Enthesitis | 27 (19) |
| Dactylitis | 26 (18) |
| Axial arthritis | 17 (12) |
| None recorded | 11 (8) |
| Swollen joint count, median (IQR) | (n=128) |
| 68/66 or 78/76 | 7.5 (5.0–12.0) |
| 28/28 | 6.5 (3.8–8.5) |
| Tender joint count, median (IQR) | (n=128) |
| 68/66 or 78/76 | 17.5 (8.0–27.3) |
| 28/28 | 15.5 (10.0–22.3) |
| Physician global assessment score, median (IQR) | (n=90) |
| 5-point Likert scale | 4 (3–4) (n=77) |
| 100-point VAS | 39.5 (28.5–53.5) (n=6) |
| 10-point VAS | 3 (3.0–3.5) (n=7) |
| Patient global assessment score, median (IQR) | (n=113) |
| 5-point Likert scale | 4 (3–4) (n=79) |
| 100-point VAS | 65.0 (42.5–75.0) (n=34) |
Data are presented as n (%) unless stated otherwise. IQR: interquartile range; VAS: visual analog scale.